Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease

David G Levitt
Michael D Levitt

1Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, USA; 2Research Service, Veterans Affairs Medical Center, Minneapolis, MN, USA

Abstract: Serum bilirubin measurements are commonly obtained for the evaluation of ill patients and to screen for liver disease in routine physical exams. An enormous research effort has identified the multiple mechanisms involved in the production and metabolism of conjugated (CB) and unconjugated bilirubin (UB). While the qualitative effects of these mechanisms are well understood, their expected quantitative influence on serum bilirubin homeostasis has received less attention. In this review, each of the steps involved in bilirubin production, metabolism, hepatic cell uptake, and excretion is quantitatively examined. We then attempt to predict the expected effect of normal and defective function on serum UB and CB levels in health and disease states including hemolysis, extra- and intrahepatic cholestasis, hepatocellular diseases (eg, cirrhosis, hepatitis), and various congenital defects in bilirubin conjugation and secretion (eg, Gilbert’s, Dubin–Johnson, Crigler–Najjar, Rotor syndromes). Novel aspects of this review include: 1) quantitative estimates of the free and total UB and CB in the plasma, hepatocyte, and bile; 2) detailed discussion of the important implications of the recently recognized role of the hepatic OATP transporters in the maintenance of CB homeostasis; 3) discussion of the differences between the standard diazo assay versus chromatographic measurement of CB and UB; 4) pharmacokinetic implications of the extremely high-affinity albumin binding of UB; 5) role of the enterohepatic circulation in physiologic jaundice of newborn and fasting hyperbilirubinemia; and 6) insights concerning the clinical interpretation of bilirubin measurements.

Keywords: liver, conjugation, diazo, albumin, Rotor

Introduction

The yellow color imparted to the skin and sclera by elevations of plasma bilirubin has piqued the interest of physicians since the time of Hippocrates. Quantitation of serum bilirubin as a diagnostic test awaited the description of the diazo reagent measurement of direct and indirect bilirubin by van den Bergh and Muller in 1916. An additional 40 years elapsed before direct and indirect reacting bilirubins were shown, respectively, to be the glucuronide-conjugated (CB) and unconjugated (UB) forms of this molecule. An enormous body of research carried out over the last 100 years has elucidated the major features of bilirubin biochemistry and physiology. However, interest in this topic has waned in recent years, and most physicians have only a rudimentary understanding of the physiological/biochemical mechanisms that determine serum CB and UB concentrations in health and disease. Recently, such understanding has taken on greater clinical importance in that the precise serum bilirubin concentration is a major component in the calculation of the Model for End-Stage Liver Disease (MELD), Child–Pugh, Maddrey, and FibroTest discriminant...
function scores that are used to direct therapy and predict the prognosis of patients with liver disease.

Many of the important concepts concerning bilirubin excretion were published 40 or more years ago (see the 1990 edition of Zakim and Boyer's *Hepatology: A Textbook of Liver Disease*) and are no longer emphasized in current publications. In the present review, we have incorporated these older data with knowledge acquired since 1990, primarily of the genetic characterization of the bilirubin transport proteins. The more novel aspect of this review is our attempt to quantitatively characterize each of the different pathways involved in bilirubin excretion and to show how these pathways interact to produce the serum bilirubin values observed in health and disease. Figure 1 diagrams the steps involved in bilirubin elimination – from its formation from heme to its gastrointestinal and renal excretion as glucuronide conjugates. This complex process involves multiple membrane transporters and enzymes. In addition to the normal transport pathways indicated by the solid lines, three other pathways (dashed lines) may become important when there is a reduced capacity to conjugate or excrete bilirubin. The terms in red refer to the selected, well-defined pathological conditions that alter the different pathways, each of which is discussed in detail in this review. While a wide range of bilirubin concentrations are observed both in health and disease, typical representative values for total bilirubin (TB), UB, and CB in normal and pathological conditions are listed in Table 1. Clinically, bilirubin concentrations are commonly expressed as mg/dL rather than umol/L (µM). One mg/dL of bilirubin is equivalent to 17.2 µM. Despite different molecular weights, the conversion factor is the same for UB and CB because mg/dL units represent only the weight of the bilirubin moiety of the conjugated molecule. For ease of understanding by clinicians, we employ mg/dL units when discussing measurements used in medical practice, whereas molar units may be utilized for more basic calculations.

**UB: production, solubility, albumin binding, and pharmacokinetics**

Bilirubin (a tetrapyrrole chain) is created when the alpha-methylene bridge of the tetrapyrrole ring of heme is cleaved by heme oxygenase. This reaction releases the alpha-methylene carbon as carbon monoxide (CO) and biliverdin, which is rapidly reduced to bilirubin via the activity of biliverdin reductase. Since heme catabolism is the only endogenous source of CO in humans, and this CO is quantitatively excreted in expired air, breath CO measurements (corrected for ambient CO) provide a noninvasive means of estimating bilirubin production and red blood cell (RBC) turnover, a measurement not provided by any other simple methodology.

About 250 mg/day of bilirubin is produced by normal adult humans; roughly 75% of this is derived from circulating hemoglobin, while the other 25% is derived from catabolism of other heme compounds, primarily cytochromes. Until recently, the breakdown of heme to bilirubin was considered simply to be a step in the elimination of hemoglobin. More recent evidence, however, points to the importance of heme turnover as a major source of bilirubin. Recent studies suggest that a large fraction of heme turnover is associated with the degradation of cytochromes and other heme proteins.

Figure 1 Major pathways involved in bilirubin production, conjugation, and excretion.

Notes: Both the UB and CB forms are bound by albumin in the plasma and interstitial space and by ligandin in the hepatocyte. The mechanism responsible for transporting unconjugated bilirubin into the hepatocyte has not been identified. Bilirubin is conjugated in the liver by the UGT family of enzymes. CB is secreted into the bile by the ATP-coupled ABCC2/MRP2 transporter. CB can be recycled from the hepatocyte to plasma, leaving via, eg, the ABCC3/MRP3 transporter, and taken up by the OATP transport proteins. Renal excretion of CB can become important in obstructive diseases. The terms in red refer to the pathological conditions that influence the different pathways. The solid arrows represent the normal physiological pathways. The black dashed arrows indicate the enterohepatic circulation of bilirubin, which may occur in certain pathological conditions. The green dashed arrows indicate a possible UB excretory pathway that may be important in conditions of severe hyperbilirubinemia.

**Abbreviations:** ATP, adenosine triphosphate; CB, conjugated bilirubin; GI, gastrointestinal; UB, unconjugated bilirubin; UGT, uridine diphosphate glucosyltransferase; ?, the mechanism is unknown.
senescent heme. However, it is now recognized that the products of this reaction have important regulatory functions: CO is an intracellular gaseous messenger, analogous to the well-accepted function of nitric oxide,9–11 and bilirubin is a free radical scavenger with antioxidant and anti-inflammatory actions.12,13 Mancuso and Barone have presented a detailed review of the oxygenase/biliverdin reductase reaction with a focus on the possible sites of clinical and pharmacological regulation of this reaction and the resulting control of the local concentrations of CO and/or bilirubin.14 In addition, biliverdin reductase has a variety of other functions, including acting as a transcription factor and an activator of protein kinase C and other signaling pathways.15 Although it was suggested that there was a redox cycling between bilirubin and biliverdin,16 this is now thought to be of minor importance.17,18 In addition to bilirubin’s antioxidant properties, both free and albumin-bound bilirubin can scavenge NO and NO-related species.19–21 These myriad clinical actions of bilirubin suggest that there is teleological benefit to the seemingly counterproductive conversion of water-soluble, readily excretable bilirubin to highly water-insoluble UB that must be conjugated with glucuronides to become water soluble and hence excretable by the liver and kidney. Support for a beneficial effect of UB is provided by multiple studies showing a negative association between serum bilirubin concentration and various diseases such as coronary artery disease in subjects with normal liver function,22–24 as well as in subjects with Gilbert’s syndrome.25

UB is formed in reticuloendothelial cells, transported to the liver where it is conjugated to glucuronides, and then secreted into the canaliculi. UB has unusual physical chemical properties. As a dicarboxylic acid, this molecule would be expected to have high water solubility; however, unusual intramolecular hydrogen bonding ties up the hydrophilic groups. Thus, UB has a very low water solubility, and in some respects behaves as if it were a lipophilic solute.26 The water solubility at pH 7.4 is experimentally uncertain, with estimates ranging from 7 nM27 to 100 nM.28 As expected for a lipophilic solute, UB has a high octanol-buffer partition ratio of about 23 at pH 8.29 and a high permeability through lipid bilayer membranes,30 which is manifested clinically by its ability to cross the blood–brain barrier.31 This membrane permeability prevents secretion of high concentrations of UB by the liver or kidney, since UB would rapidly back-diffuse into the blood, hence the need for glucuronide conjugation to water-soluble CB prior to excretion. In contrast to most hydrophobic compounds, bilirubin has a low partition in olive oil and is not taken up by adipose tissue,27 suggesting that the hydroxyl group of octanol accounts for its ability to solubilize UB. The insolubility of UB in adipose tissue limits the distribution space of UB to only the albumin space – about 9 L in normal subjects.31 As a result, plasma UB concentrations fluctuate far more rapidly than would be expected for a typical lipid-soluble molecule.

UB is solubilized in serum via a very tight linkage to albumin. The measurement of the albumin dissociation constant (Kd) is uncertain, with reported values ranging from 8 to 160 nM.32 We will use the value of 17 nM recommended in the authoritative review by Brodersen and Stern.27 Although free serum UB concentration cannot be directly measured, based on this Kd, the unbound concentration is estimated to be in the order of 0.16 nM, about 1/50,000 of the total serum UB. The

### Table 1 Representative human plasma bilirubin values

| Condition                        | Total         | Unconjugated | Conjugated | % conjugated |
|----------------------------------|---------------|--------------|------------|--------------|
| Normal mean (HPLC)              | 6.2 (0.36)    | 6.0 (0.35)   | 0.2 (0.012)| 3.2          |
| Normal range (HPLC)             | 2.0 (0.1)–13 (0.7)| 2.0 (0.1)–13 (0.7)| 0.06 (0.003)–0.5 (0.03)|          |
| Normal range (diazo)            | 3.5 (0.2)–20 (1.2)| 3 (0.15)–15 (0.9) | 0.35 (0.02)–4.8 (0.28) |          |
| Gilbert’s syndrome (HPLC)       | 32 (1.8)      | 31.5 (1.84)  | 0.29 (0.017)| 0.9          |
| Crigler–Najjar type I (HPLC)    | 316 (18.5)    | 316 (18.4)   | 0.7 (0.04) | 0.2          |
| Hemolytic anemia (HPLC)         | 26 (1.52)     | 25 (1.46)    | 1 (0.058)  | 3.8          |
| Chronic alcoholic cirrhosis (HPLC)| 68 (4)        | 55 (3.2)     | 13.6 (0.8) | 20           |
| Chronic viral hepatitis (diazo) | 75 (4.4)      | 27 (1.6)     | 48 (2.8)  | 64           |
| Dubin–Johnson syndrome (diazo)  | 69 (4.0)      | 28 (1.64)    | 40 (2.34) | 59           |
| Rotor syndrome (diazo)          | 110 (6.4)     | 25 (1.46)    | 85 (5.0)  | 77           |
| Common duct stone (HPLC)        | 150 (8.8)     | 10 (0.58)    | 140 (8.18)| 93           |
| Bilay atresia (diazo)           | 340 (20)      | 85 (5)       | 260 (15)  | 75           |
| Cholestasis of pregnancy (diazo)| 14.2 (0.83)   | 7.4 (0.43)   | 6.8 (0.4) | 48           |
| Primary biliary cirrhosis (diazo)| 170 (10)      | 51 (3.0)     | 120 (7)   | 70           |

**Notes:** Concentrations are in µmol/L and (in parentheses) mg/dL. Analytic chromatographic (HPLC) values are presented when they were available, otherwise the standard diazo assay values were used.

**Abbreviation:** HPLC, high-performance liquid chromatography.
tight albumin binding of UB precludes glomerular filtration; thus, urine remains normal in appearance in icteric states resulting from hemolysis or genetic conjugating defects, conditions characterized by increased concentrations of only UB (Table 1). Since the normal plasma albumin concentration is 0.6 mM, UB concentrations of about 0.5 mM (29 mg/dL) are required to saturate the single high-affinity binding site per albumin molecule. This value is seldom achieved, with the exception of conditions in the newborn and patients with severe, congenital conjugation defects resulting in permeation of the blood–brain barrier and kernicterus. The molecular mechanisms of the bilirubin-induced neuronal cell injury are poorly understood, but likely include mitochondrial and/or endoplasmic reticulum membrane damage leading to increased intracellular Ca++. It has also been suggested that the neurotoxic actions of bilirubin may result from its ability to modulate neurotrophin redox signaling.

The affinity of albumin for UB is several orders of magnitude stronger than its affinity for most other drugs and endogenous compounds. It has not been fully appreciated that this strong binding produces severe but finite constraints on the rate at which UB distributes between plasma and tissue spaces. For example, Berk et al presented a detailed description of the plasma kinetics of an intravenously infused bolus of 14C-labeled UB, and Figure 2 shows a typical disappearance curve of labeled UB from the serum of a normal subject. Berk et al then developed a three-compartment, eight-parameter model representing the plasma, liver, and extravascular space to explain the somewhat unusual time course of UB disappearance from the plasma. For what they assumed to be a totally albumin-bound solute, their model had an unusually rapid exchange rate between plasma and extracellular space (about a 9-hour time constant). This required Berk et al to postulate the existence of a “rapidly exchanging” albumin pool to explain the 9-hour time constant, whereas the commonly accepted time constant for albumin is about 24 hours.

What was seemingly not recognized by Berk et al was that the observed UB exchange was consistent with movement of just the very small, but not negligible, unbound UB without invoking any albumin exchange. It can be shown that the fractional equilibration (FrEq) of UB between the plasma and interstitial albumin in a single pass through the capillary is described by:

$$\text{FrEq} = 1 - \exp(-f_p PS/F),$$

where $f_p$ is the fraction free in plasma; S and F are the organ capillary surface area and flow, respectively; and P is the intrinsic capillary permeability (ie, if there were no albumin binding). The fraction that equilibrates is zero for an impermeable solute ($P=0$), and is 1 for an infinitely permeable solute. A solute can have a high intrinsic permeability ($P$), but a low fractional equilibration if it is highly protein bound (ie, has a small $f_p$). UB with an $f_p$ of about $2\times10^{-5}$ presents an extreme example of this phenomenon.

A physiologically based pharmacokinetic (PBPK) model for humans developed by one of the authors (DGL) describes the pharmacokinetics of an albumin-bound solute in terms of the predicted capillary permeability, known organ flows and volumes, plasma and interstitial albumin concentration, and the plasma unbound fraction. Kinetics are assumed to be independent of the slow albumin plasma–tissue exchange. This model was previously used to estimate the capillary permeability of albumin-bound antibiotics. Figure 2 demonstrates the excellent fit of UB plasma disappearance predicted by the PBPK model with the experimental data of Berk et al. It should be emphasized that this analysis employs the previously established normal human PBPK parameters and has only two adjustable parameters: liver clearance and fractional equilibration for skeletal muscle. In contrast, the three-compartment model of Berk et al had eight adjustable parameters. Figure 3 shows a plot of the time course of the PBPK model concentrations of free bilirubin in plasma and in two representative interstitial compartments: muscle (small interstitial space) and skin (large interstitial space). For times longer than about 100 minutes, the interstitial free concentration is greater than that of the plasma, and the slow movement of this interstitial
UB back into the plasma is responsible for the slow rate of decay of the plasma UB.

**CB: albumin binding, renal excretion, covalent albumin binding, and clinical measurements**

The standard clinical measurement of CB as “direct”-reacting bilirubin is based on the assumption that only CB reacts “directly” with the diazo reagent, ie, without an accelerator. However, compounds other than CB are measured as direct-reacting bilirubin. Measurements using analytic liquid chromatographic (high-performance liquid chromatography [HPLC]) measurements of the mono- and diconjugated bilirubin fractions indicate that CB comprises only about 3% of TB, or about 0.012 mg/dL (about one-eighth of the direct reacting value of 0.1 mg/dL) for an “average” subject with a TB of 0.4 mg/dL. Most of the values listed in Table 1 are based on HPLC measurements. One of the rare comparisons of the HPLC and diazo measurements of CB described the rising plasma CB in guinea pigs following bile duct obstruction. Before obstruction, CB was undetectable (<0.006 mg/dL) by HPLC measurement, while the diazo CB was 0.1 mg/dL (similar to normal human plasma). As serum CB rose after obstruction, the diazo CB remained about 0.1 mg/dL greater (similar to normal human plasma). As serum CB rose after obstruction, the diazo CB was 0.1 mg/dL
greater than the HPLC measurement, suggesting a constant background contaminant (about 0.1 mg/dL), possibly representing cross-reacting UB. When CB approaches 1 mg/dL or greater, this 0.1 mg/dL artifact becomes negligible and the direct diazo measurement accurately quantitates CB.

Figure 1 diagrams the major pathways involved in bilirubin conjugation and excretion. In addition to the normal bile CB excretion, the kidney can also excrete CB, since the unbound fraction of CB is freely filtered at the glomerulus and CB has a high water solubility, reaching concentrations of 500 mg/dL (7 mM) in gall bladder bile. However, the combination of the very low normal plasma concentration of CB in conjunction with about 99% albumin binding renders urine bilirubin unmeasurable in healthy subjects. However, in some pathological conditions, serum CB concentration reaches a level that allows the urinary tract to become the major/sole excretory pathway. This was clearly illustrated by canine experiments showing that, following total biliary obstruction, plasma CB concentration rose to a steady-state value of only about 3 mg/dL (more than 70% conjugated), at which time the renal excretion of CB roughly equaled the expected bilirubin production. In these dogs, the CB renal clearance (CB_{\text{cl}}) was about 1.7% of the creatinine clearance, which was in good agreement with the experimental dialyzable free fraction of 1.6% that is observed in dogs. As expected, the plasma steady-state level was inversely related to the creatinine clearance. For humans, the dialysis value of about 0.7% free was consistent with the experimentally determined CB_{\text{cl}} of 0.7% of the creatinine clearance. In infants with biliary atresia, CB rises to about 15 mg/dL (260 µM [Table 1]), the predicted value if the kidney accounted for all excretion of bilirubin with a CB_{\text{cl}} of 0.7% of creatinine clearance. In these infants, 45%–71% of intravenously administered 14C-labeled bilirubin was recovered in the urine over 10 days.

At first glance, it is surprising that a CB_{\text{cl}} of only 0.7% of that of creatinine can bring about bilirubin homeostasis. However, a creatinine clearance of 120 mL/minute extrapolates to a glomerular filtration rate of 173 L per day; 0.7% of this value yields a CB_{\text{cl}} (if no reabsorption) of 1.2 L per day. When the serum CB reaches a level of 20 mg/dL, the daily renal excretion of bilirubin (200 mg/L × 1.2 L) equals 240 mg of bilirubin, roughly the normal production rate of this compound.

The rate at which plasma CB concentration would be expected to rise with no biliary elimination of bilirubin, eg, complete biliary tract obstruction, can be predicted, assuming rapid equilibration into a distribution space (V_{\text{eq}}) equal to the albumin space of 9 L. The plasma concentration as a function of time (CB(t)) should rise exponentially to a steady state with a time constant of $T = V_{\text{eq}}/CB_{\text{cl}}$:

$$CB(t) = (R/CB_{\text{cl}}) \left[1 - \exp\left(-t/T\right)\right],$$

where R is the rate of bilirubin production. In the normal human, where $R = 250$ mg/day and $CB_{\text{cl}} = 0.007×120$ mL/
minute = 0.84 mL/minute, the plasma CB should rise initially at a rate of \( R/V_{cb} = 2.8 \) mg/dL per day with a time constant \( T \) of 7.4 days, and should reach a steady state of \( R/CB_{d} = 20 \) mg/dL after about two time constants, or 15 days. Higher rates of rise or higher steady-state values indicate abnormally rapid bilirubin production and/or decreased creatinine clearance, both of which may occur in severe cholestatic liver disease.

The covalent linkage of CB with albumin (referred to as \( \delta \)-bilirubin) first recognized by Weiss et al in 1983 \(^{49} \) is measured as “direct” (conjugated) bilirubin with the diazo reaction. The half-time of \( \delta \)-bilirubin is the same as that of albumin (13- to 18-day half-time). \(^{50} \) The percentage of the serum CB composed of \( \delta \)-bilirubin increases with the duration of conjugated hyperbilirubinemia, reaching steady-state levels of as great as 40% in long-standing hyperbilirubinemia. \(^{49} \) When the obstruction to bile flow is alleviated, this fraction can rise to greater than 80% as \( \delta \)-bilirubin becomes concentrated by the hepatic excretion of the non-covalently linked CB, and serum CB declines very slowly despite restoration of bile flow.

**Bilirubin glucuronidation and UB excretion**

Figure 1 diagrams the major pathways involved in bilirubin conjugation and excretion. Bilirubin production occurs primarily in the spleen, and a loss of first-pass hepatic metabolism has been proposed as a cause of unconjugated hyperbilirubinemia in cirrhotic patients with varices. \(^{51} \) However, first-pass metabolism is important only for compounds with a high-percentage extraction by the liver. The normal UB plasma clearance of about 47 mL/minute is only about 5% of liver plasma flow, \(^{38} \) thus first-pass effects can be neglected.

Glucuronidation is a major pathway of liver metabolism, representing about 45% of all phase II (ie, conjugating) liver enzymes. \(^{52} \) Glucuronidation of bilirubin is carried out by the uridine diphosphate glycosyltransferase (UGT) family of enzymes that catalyze the conjugation of a very wide variety of substrates. \(^{58} \) About 11% of UGT is \( UGT1A1 \), an isozyme that specifically catalyzes the covalent linkage of glucuronic acid to one or both propionic acid side chains of bilirubin. \(^{54,55} \) A large range of mutations in \( UGT1A1 \) (Crigler–Najjar) and its promoter (Gilbert’s) produce a variety of phenotypes ranging from the complete absence of bilirubin conjugation (Crigler–Najjar type I) to a condition with minor (up to five-fold) increases in serum UB (Gilbert’s syndrome) (Table 1). \(^{56} \)

The ratio of monoconjugated-to-diconjugated CB in bile is about 0.37 in normal subjects and rises to 0.94 in those with Gilbert’s syndrome. \(^{57} \)

Surprisingly, the mechanism by which UB enters the liver remains an enigma. Despite an intensive search for proteins that actively transport UB into the hepatocyte, no transporters have been identified. \(^{58,59} \) In this era of genome-wide targeted gene screening, \(^{56} \) the inability to identify a transporter raises the possibility that such a protein does not exist. Another argument against an active transport system is that it would have to work against leakage of the bilayer permeable \(^{60} \) bilirubin out of the cell. For these reasons, it is useful to consider the quantitative implications of the proposal that passive diffusion accounts for the hepatocyte uptake of UB. \(^{10,61} \)

The free plasma concentration of UB of only about 0.16 nM puts severe constraints on a simple passive diffusion mechanism. A quantitative example of this constraint is provided by calculation of the predicted conjugation rate for a UB concentration of 0.16 nM. Using human liver biopsies, the \( V_{max} \) for bilirubin glucuronidation is about 1 mg/hour/g liver, \(^{62,63} \) corresponding to about 36,000 mg/day for a 70 kg human. Since these assays were carried out in the presence of detergents (digitonin or Triton X-100) and optimal cofactors, this \( V_{max} \) probably overestimates the true in vivo value. \(^{52} \) The determination of the \( UGT1A1 \) half maximal binding concentration (Km) is uncertain because of bilirubin instability, binding, and insolubility. Zhou et al \(^{64} \) recently estimated a Km of 0.2 µM for purified recombinant UGT1A1. Since some nonspecific bilirubin binding by the recombinant assay medium could not be ruled out, this Km may be greater than the true value. Using these values for \( V_{max} \) and Km, the predicted rate of glucuronidation at a free UB concentration of 0.16 nM is only about 28 mg/day, or one-ninth of the requisite value of 250 mg/day. \(^{38} \) This estimate assumes that the entire hepatocyte is exposed to a 0.16 nM concentration of UB. The actual exposure of the liver to UB can be estimated from a calculation of the thickness of the rate-limiting diffusive unstirred layer (\( L_{us} \)) between the sinusoids and the site of UB metabolism in the hepatocyte:

\[
\text{Glucuronidation rate} = (D/S/L_{us}) \times [\text{UB}]_{\text{free plasma}} \tag{3}
\]

Using a glucuronidation rate of 250 mg/day, aqueous diffusion coefficient (D) of \( 3 \times 10^{-6} \) cm²/second, sinusoidal surface area (S) for 70 kg human of 4.5×10⁵ cm², \(^{65} \) and free plasma UB concentration ([UB]_{free plasma}) of 0.16 nM, the limiting unstirred layer is only 0.42 µm. Thus, the UB concentration falls from the plasma free concentration (at the sinusoidal membrane)
to zero over a 0.42 μm thickness, and only a small fraction of the hepatocyte (about 10%, assuming a 25 μm cell diameter) would have any UB concentration exposure. Thus, glucuronidation of UB seemingly could not occur at the observed rate if hepatocyte uptake relied solely on passive diffusion and the normal free UB concentration was 0.16 nM.

Direct measurements of the hepatocyte bilirubin concentration provide the strongest evidence for an active transport mechanism that raises the free UB concentration in the hepatocyte to a value greater than that in plasma. In the rat liver, the total (bound plus free) UB is about 1 μM, which is twice the rat serum concentration. There are no direct measurements of the hepatocyte free UB concentration, but it can be estimated from the following arguments. In the hepatocyte, UB is bound by several abundant cytosolic proteins that were initially referred to as “ligandins” and later identified as glutathione S-transferases. The ligandin bilirubin Kd is about 5 μM, which is much weaker than that of albumin (Kd = 17 nM). In addition, the ligandin concentration is about 0.07 mM, or one-tenth that of serum albumin. Using these estimates, the free hepatocyte unconjugated concentration should be about 0.07 μM – about 400 times the free plasma value.

It has been shown that the glucuronidation rate is proportional to the free (not total) plasma concentration of UB. For this case, in the steady state:

\[
\text{Heme catabolism} = \text{Glucuronidation rate} = k \ [UB]_{free} = k \ Freefr \ [UB]_{tot} \\
\rightarrow [UB]_{tot} = (\text{heme catabolism})/(k \ Freefr),
\]

where k is the first-order glucuronidation rate constant and Freefr is the free plasma fraction. This relation predicts that the total plasma UB concentration should be inversely proportional to the free fraction (assuming a constant input from heme catabolism). This relationship was confirmed in the rat, where the free fraction was varied by infusion of salicylic acid or sulfisoxazole, competitive inhibitors of albumin binding of UB. As predicted by the above relation, doubling the free fraction reduced the total UB concentration by a factor of two but did not change the free concentration. A clinical illustration of this effect is seen in renal failure patients on dialysis. In such patients, the total plasma UB concentration was only one-quarter of the normal value, and the free fraction was four- to eightfold greater than normal, as predicted from the above relation. This increase in free fraction (decrease in albumin affinity) in chronic renal failure has been attributed to plasma accumulation of organic acid “uremic toxins” such as 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid. Such compounds, which compete for the high-affinity albumin binding site for UB, reach concentrations of 0.4 mM.

The above results show that the glucuronidation rate is proportional to the serum free UB concentration and, therefore, the total UB is related to the albumin concentration (Alb) by the following relation:

\[
[UB]_{tot} = (\text{heme catabolism}) \times [Alb]/(k \ Kd),
\]

where Kd is the UB albumin equilibrium dissociation constant. Thus, total serum UB should be proportional to the albumin concentration. Since serum albumin is reduced in most chronic diseases, total UB should be concomitantly reduced if the other factors in the above relation were unchanged. Although it has been suggested that the

| Plasma | Hepatocyte | Bile duct |
|--------|------------|-----------|
| Unconjugated bilirubin =6 μM Free ≈ 0.16 nM | Unconjugated bilirubin =1 μM Free ≈ 0.07 μM | Unconjugated bilirubin ≈ 0.2 μM Free ≈ 0.07 μM |
| Conjugated bilirubin =0.2 μM Free ≈ 0.0035 μM | Conjugated bilirubin =1 μM Free ≈ 0.05 μM | Conjugated bilirubin =500 μM Free ≈ 500 μM |

Figure 4 Estimated normal human total and free (unbound) conjugated and unconjugated bilirubin in the plasma, hepatocyte, and bile duct.
rate-limiting step in hepatic bilirubin uptake is the albumin dissociation rate, this implies that the glucuronidation rate should be proportional to the total (not free) serum UB, and is therefore ruled out by the above observation.

UGT1A1 has a lower affinity for a variety of other xenobiotics than for UB and a weak competitive inhibition of UB has been reported, eg, for indinavir and ibuprofen. Probably the most important competitive inhibitors are the mono- and diglucuronides of bilirubin. Conditions that increase serum CB may produce very large increases (eg, 700-fold) in the hepatocyte CB concentration (see “CB transport from hepatocyte to blood”). Thus, competitive inhibition of conjugation might explain the rise in serum UB seen in cholestatic conditions that seemingly would act primarily on CB excretion and not alter UGT1A1 activity. This is discussed in more detail in the concluding section on the clinical implications of bilirubin metabolism (“Summary and clinical implications”).

As discussed in the section “CB: albumin binding, renal excretion, covalent albumin binding, and clinical measurements”, when the liver is unable to clear CB, the steady state is established primarily by urinary excretion of CB. In contrast, homeostasis for UB cannot be achieved via renal excretion, since only the trivial free fraction of UB could enter the urine and this free UB would not be concentrated due to back-diffusion from the tube. For example, type I Crigler–Najjar subjects with a nearly complete absence of conjugating capacity excrete only about 5% of a 14C bilirubin dose in the urine, and the steady state is established by gastrointestinal excretion as evidenced by a total fecal bile pigment excretion similar to that of normal subjects. The mechanisms responsible for this intestinal excretion are poorly understood. There are two possible pathways. The first is via biliary secretion of bilirubin and bilirubin metabolites. Since the TB concentration of bile in type I Crigler–Najjar subjects was only about one-fifth of normal, biliary secretion can account for only a small fraction of total excretion. Although Crigler–Najjar bile also contains significant amounts of bilirubin derivatives, these compounds are thought to be derived primarily from enterohepatic circulation of metabolites formed in the intestine and do not contribute to net bilirubin excretion.

The second intestinal excretion pathway for UB in type I Crigler–Najjar subjects is diffusion from the blood into the gut down a diffusion gradient maintained by bacterial and intestinal metabolism of luminal UB (indicated by the green dashed line in Figure 1). For Gunn rats (homologous to Crigler–Najjar) with external biliary diversions, fecal bile pigment concentration was more than 50% of that of control Gunn rats with no external drainage. In contrast, in normal (Wistar) rats with diversion of all bile flow, there were no detectable stool bile pigments. This strongly implies that more than 50% of the bilirubin clearance in Gunn rats is by transport from blood to intestine, presumably via passive diffusion. Direct support for the concept that appreciable UB diffuses into the intestine is provided by the observation that oral calcium phosphate, which binds UB and presumably increases the serum to lumen diffusion gradient, is very effective in lowering UB in Gunn rats and produces a small but statistically significant fall in serum UB in Crigler–Najjar type I patients. Recently, it has been shown that Orlistat (Roche, Woerden, the Netherlands) (a lipase inhibitor) significantly increases transmural intestinal UB excretion in Gunn rats, presumably by increasing the blood-to-lumen diffusion gradient via UB binding by undigested fat.

The following relationship estimates the plasma free UB concentration required to clear the total human daily bilirubin production rate (R=250 mg/day) by passive diffusion into the small intestine:

\[
R = P S \left( UB_{plasma,free} - UB_{intestine,free} \right) = P S UB_{plasma,free},
\]

where P and S are the small intestinal permeability and surface area, respectively, and the last equality assumes that the intestinal concentration is maintained close to zero by intestinal metabolism. Using \( P=2\times10^{-3} \text{ cm/second} \) determined from the rate of human intestinal absorption of highly permeable (diffusion-limited) drugs and \( S=4,400 \text{ cm}^2 \), the free plasma UB would need to be about 0.56 \( \mu \text{M} \). Although this value is much lower than the typical total UB found in Crigler–Najjar subjects of about 300 \( \mu \text{M} \), albumin binding will reduce the corresponding free UB concentration to only about 0.051 \( \mu \text{M} \), or one-tenth of the requisite 0.56 \( \mu \text{M} \) required to bring about bilirubin homeostasis (assuming a serum albumin of 400 \( \mu \text{M} \) and an albumin dissociation constant of 17 nM). Although UB definitely reaches concentrations that saturate albumin in some type I Crigler–Najjar subjects, the mechanism establishing the steady state at lower UB concentrations (eg, 300 \( \mu \text{M} \)) is uncertain. Given that homeostasis is achieved in these patients, it seems necessary to postulate that free plasma UB must reach a concentration of roughly 0.56 \( \mu \text{M} \),
possibly via some mechanism that influences albumin binding of UB.

**Bilirubin transport from hepatocyte to bile**

CB is transported across the apical membrane of the hepatocyte into the bile by the multidrug resistance-associated protein (MRP) 2, a member of the superfamily of adenosine triphosphate-binding cassette transporters (ABC), also referred to as ABCC2 (Figure 1). This transport system has recently been reviewed in depth by Nies and Keppler and Jennitz et al, and our focus will be on the implications of this system for the general pharmacokinetics of bilirubin transport in normal and pathological conditions.

Free hepatocyte CB concentration has not been directly measured. In whole rat liver, the total CB concentration is about 1 µM. Most of this bilirubin is intracellular, since the contribution from contents of intrahepatic bile ducts is said to be small. Intracellular CB is tightly bound to ligandin with a dissociation constant of about 3 µM, similar to that for UB. Assuming a ligandin concentration of 0.07 mM, the free hepatocyte concentration is about 0.04 µM. Although MRP2 transports a large variety of conjugated substrates, it has the highest affinity for CB with a Km for the mono- and diglucuronide of 0.7 and 0.9 µM, respectively. Bile secreted by the liver has a CB concentration of about 500 µM, which is nearly all free. Thus, ATP-coupled active transport by MRP2 produces a relatively enormous, roughly 10,000-fold increase in free CB concentration. These estimates of bilirubin concentrations are summarized in Figure 4.

Less than 1% of the bilirubin in the bile of normal subjects is unconjugated. Since deconjugation occurs spontaneously in bile incubated at 37°C, even this 1% may be artifactually produced during sampling and analytical procedures. In contrast, the very high serum UB concentration in Crigler–Najjar syndrome with severe UGT1A1 deficiency is seemingly in diffusion equilibrium with the hepatocyte, and bile and bile UB concentrations may reach 34 µM and constitute 50% of the total bile bilirubin. It is important to maintain very low concentrations of biliary UB since this poorly water-soluble compound is seemingly an initiating factor in gallstone formation, as evidenced by the high prevalence of gallstones in subjects with bilirubin conjugating defects.

Consistent with this observation, in subjects with normal serum bilirubin concentrations, the bilirubin in both pigment and cholesterol gallstones is >95% unconjugated, indicating that precipitated UB is concentrated in gallstones.

The strongest evidence supporting the primary role of MRP2 in the transport of CB into the bile canaliculus is the high serum concentrations of CB observed with mutations in the MRP2 gene in Dubin–Johnson syndrome. Patients with this syndrome characteristically have a pigmented liver and roughly tenfold increase in total plasma bilirubin concentrations, consisting of a fourfold elevation in UB and a 200-fold elevation in CB (Table 1). At a 2.34 mg/dL plasma CB, about 30 mg/day of bilirubin will be excreted by the kidney (see “CB: albumin binding, renal excretion, covalent albumin binding, and clinical measurements”), which is roughly 12% of the daily production. Thus, most of the bilirubin must still be excreted by the liver. This is consistent with the observation that rats with a similar genetic deficiency of MRP2 have a near-normal rate of biliary secretion of CB even though the rat plasma TB concentration is 25 times normal. This biliary excretion may reflect the activity of a second, low-affinity ATP-independent transporter that partially compensates for the loss of MRP2.

**CB transport from hepatocyte to blood**

A recent, surprising observation suggests that defects in the sinusoidal transmembrane organic anion-transporting polypeptides (OATPs) are an important determinant of serum CB concentrations. In contrast to the ATP-coupled ABC transporter family (eg, canalicular membrane MRP2) that facilitates cellular efflux, the OATPs are members of the solute carrier (SLC) family that primarily promote cellular uptake of endo- and xenobiotics by a variety of tissues, including intestine, kidney, and liver. The Km of OATP1B1 for bilirubin mono- and diglucuronide is 0.1 and 0.28 µM, respectively. The mechanism, magnitude, and driving force for hepatic OATP solute transport is not known, although it is independent of both ATP and sodium. The key new finding of Van de Steeg et al and Iusuf et al was that mice with a double knockout of OATP1A1 and OATP1B1 had about a 400-fold increase in serum CB along with a 50% reduction in the rate of secretion of bilirubin in bile and a markedly increased urinary CB excretion. Subjects with Rotor syndrome similarly have simultaneous complete deficiencies in the analogous human genes OATP1B1 and OATP1B3, and the products of these genes are selectively localized to the hepatic basolateral (sinusoidal) membrane. These subjects have a conjugated hyperbilirubinemia (usually on the order of 5 mg/dL [Table 1]), but lack the liver pigment characteristic of Dubin–Johnson syndrome.

Another distinguishing...
feature of Rotor syndrome is a bromsulphthalein (BSP) clearance that is only about 15% of normal, as would be predicted if the sinusoidal OATP transport systems were required for the normal hepatic uptake of BSP. In contrast, in Dubin–Johnson syndrome, the initial hepatic uptake of BSP is close to normal, but, after about 45 minutes, there is a characteristic reflux of conjugated BSP back into blood, presumably as a result of the defect in the MRP2 canalicular excretion of conjugated BSP.

These observations with OATP deficiency raise the question of how a genetic defect that seemingly limits transport of CB into the hepatocyte produce marked increases in serum CB. Van de Steeg et al proposed that, in the mouse, 50% of the total CB produced by the liver normally cycles from the hepatocyte to the sinusoids and back to the hepatocyte before being secreted in bile. The very low plasma CB observed normally would require extremely efficient reuptake of this “regurgitated” CB by the OATP transporters. The knockout of OATP proteins prevents this reuptake, hence the elevated serum CB.

There are still many unanswered questions about this new observation. In particular, does this large and energetically demanding recycling have a biological value? Van de Steeg et al hypothesize that it serves an important function by evenly distributing the excretory load of glucuronide conjugates to all hepatocytes via the sinusoidal plasma flow. They have coined the term “hepatocyte hopping” to describe what they propose to be a general property of the hepatic handling of conjugated solutes. However, since UB is only 5% cleared in a single passage through the liver, all hepatocytes are exposed to essentially the same sinusoidal UB concentration and, assuming similar hepatocyte conjugating ability, similar concentrations of CB. Thus, it does not seem necessary to “distribute the load” of CB unless conjugation is preferentially performed by hepatocytes located in zone 1, in proximity to the inflow of blood into the sinusoid. Although entirely speculative, given that sinusoidal and canalicular flow are roughly in opposite directions, “hopping” could minimize the quantity of CB that must be transported against the increasing canalicular concentration of CB that occurs as canalicular bile flows from the hepatic vein region toward the portal area. It is also possible that this normal leak of bilirubin has no purpose and simply reflects an unavoidable leak of CB down the large electrochemical gradient that exists between the hepatocyte and blood (Figure 4). For example, there are at least five organic anion transporters (OATs) localized in the sinusoidal cell membrane (OATPB1, OATPB3, OATP2B1, OAT2, and OAT7) that are involved in the liver uptake of a myriad of organic anions. Since these transporters allow bidirectional transport, CB could leak out through these systems.

Another potential pathway for this leak of CB from hepatocyte to blood is the hepatocyte efflux ABC transporter (MRP3 (ABCC3)) (Figure 1). MRP3 transports glucuronidated xenobiotics from the liver to the plasma, where they are renally excreted. For example, in MRP3 knockout mice, the hepatic concentration of the glucuronidated metabolites of morphine and acetaminophen are markedly increased, while the plasma concentration is decreased by more than 90%. The relative importance of the renal versus the gastrointestinal excretory pathway for such compounds is determined by the relative activity of the sinusoidal (eg, MRP3) versus the canalicular (eg, MRP2) transporters. Bile duct ligation (see “Bilirubin enterohepatic circulation”) and the resultant block of the gastrointestinal pathway induces a dramatic increase in the expression of MRP3 in both rats and humans, presumably as a means of shifting the excretory pathway from the gut to the kidney. Direct evidence for the involvement of MRP3 in bilirubin recycling was provided by the observation that, in mice with a double knockout of OATP1B1 and OATP1B3, the additional knockout of MRP3 reduced plasma CB by 50%

The involvement of OATs in bilirubin homeostasis introduces a profound change in the interpretation of the serum CB concentration, both in normal and pathological conditions. The rate of OATP clearance can be estimated from a calculation of the fraction of hepatic plasma flow that must be cleared of CB to maintain the normal human serum CB of 0.012 mg/dL (Table 1) for a given rate of bilirubin recycling (R):

\[ \text{Amount recycled} = R = (\text{Flow}) \times (C_{\text{in}} - C_{\text{out}}). \]  

where \( C_{\text{in}} \) and \( C_{\text{out}} \) are the CB concentrations in the plasma entering and leaving the liver, respectively, and Flow is the liver plasma flow. Defining clearance as the dimensionless fraction of liver blood flow that is cleared (assuming that \( C_{\text{in}} \) is equal to the systemic serum CB):

\[ \text{Clearance} = 1 - \frac{C_{\text{out}}}{C_{\text{in}}} = R/(\text{Flow} \times C_{\text{in}}). \]

A value for R can be estimated from measurements made in Rotor syndrome, assuming that these subjects have normal bilirubin kinetics with the exception of negligible hepatic uptake of CB from the plasma. The plasma CB concentration of these patients is maintained at about 5 mg/dL (Table 1),
implying that, at steady state, about 25% of the 250 mg of daily production of bilirubin will be renally excreted (see “CB: albumin binding, renal excretion, covalent albumin binding, and clinical measurements”). Hence, R (the quantity of bilirubin refluxed in these subjects but recycled in normal subjects) equals 0.25×250 or 62 mg/day. Substituting this R in the above relation and assuming \( C_n \) equals the normal plasma CB concentration of 0.012 mg/dL and a normal human liver plasma flow (Flow) of 0.8 L/minute,\(^{40}\) the normal human fractional CB clearance must be about 0.36 L/minute (45% of the liver plasma flow) and about seven times greater than the human liver UB clearance. This rapid hepatic uptake of CB is quantitatively consistent with direct measurements in the rat of both unlabeled\(^{13}\) and tritiated\(^{116}\) CB clearance of about 1 mL/minute/100 g body weight, which is equivalent to a clearance of about 35% of the rat liver plasma flow and three times faster than the rat UB clearance.\(^{116}\)

The implications of this OATP CB clearance are illustrated in Figures 5 and 6. Previously, the very low normal plasma CB concentration of 0.012 mg/dL was assumed to result from a minimal leakage of CB from the hepatocyte cell and/or canaliculus into the plasma balanced by renal clearance.\(^{6}\)

Leak = Renal excretion = CB \( \times \) (renal clearance). (9)

Using a renal clearance of 0.81 mL/minute (see “CB: albumin binding, renal excretion, covalent albumin binding, and clinical measurements”) and serum CB of 0.012 mg/dL (Table 1) yields a leak of 0.14 mg/day (Figure 5A). This represents only 0.056% of the 250 mg CB excreted per day. In contrast, if there is normal OATP hepatic CB function, then the above relation should be replaced by:

Leak = CB \( \times \) (renal clearance + OATP clearance). (10)

For a serum CB =0.012 mg/dL and an OATP CB clearance of 0.36 L/minute, the leak must be 62.3 mg/day, or 25% of the daily production (Figure 5B). Uptake by OATP has even more dramatic implications for homeostasis in hepatocellular disease. For example, we will use a hypothetical patient with hepatocellular disease who has a modest serum CB elevation to 0.36 mg/dL (about 30 times normal), roughly equal to the normal serum UB concentration (Table 1). For the conventional interpretation (Figure 6A), where the CB leak is simply balanced by renal excretion, a leak of just 4.3 mg/day (1.7% of the daily 250 mg/day output) raises the serum CB to 0.36 mg/dL. In contrast (Figure 6B), if OATP CB clearance remains that of the normal liver (0.36 L/minute), the leak predicted using the above modified equation is 1,870 mg/day, or seven times the total daily UB production, which seems highly unlikely. Thus, it seems necessary to postulate that the OAT transport system ceases to function normally early in the course of conditions causing hepatocellular dysfunction. Such dysfunction could reflect OAT damage, saturation, or inability to transport against a gradient resulting from CB accumulation in the hepatocyte secondary to defects in the secretion of CB into the bile or in the canalicular transport of the secreted CB. While the specifics require further study, OAT function appears to be a major, but presently unappreciated, determinant of the serum CB concentration.

If the rates of CB influx and efflux are proportional to concentration, then, at steady state, hepatocyte CB should be directly proportional to the serum CB concentration. Furthermore, if the UB conjugation rate and CB bile export systems are also linear, then, for normal liver function, plasma CB should be proportional to the plasma UB concentration. This relationship provides an explanation for the surprising observation that serum CB tends to be a constant fraction (about 3%) of UB in both healthy and hemolyzing individuals (a fivefold range of UB [Table 1]).\(^{117}\) Even for the case of bile duct obstruction where most of the plasma CB comes from a leak of canalicular bile (see “Bilirubin enterohepatic circulation”), these influx and efflux transport systems should still establish this same steady-state hepatocyte/plasma concentration relationship.

**Cholestasis and bile duct obstruction**

Figure 7 outlines the events involved in the formation of bile. Bile salts are either synthesized in the hepatocyte or transported from the plasma to the hepatocyte by the sodium-taurocholate cotransporting polypeptide (NTCP/SLC10A1) and, to a lesser extent, by the sodium-independent OATs.\(^{118,119}\) The bile salts are then pumped into the canalicular space by the ATP-coupled bile salt export pump (BSEP/ABCB11), which is the key protein in bile formation.\(^{120}\) The osmotic load of these bile salts along with a minor contribution from bilirubin and other glucuronides transported by the MRP pumps then draws in water and electrolytes. The relative importance of the cellular versus paracellular pathway (see Figure 7) for this osmotic water transport is unclear. In vitro measurements have shown that the hepatocyte cell membrane has a high osmotic water permeability – large enough that the relatively small solute gradients produced
by bile salt secretion could account for the observed biliary flow rates.\textsuperscript{121} The tight junctions between hepatocytes are cation selective, allowing free movement of Na\textsuperscript{+}, and are impermeable to bile salts and glucuronides. However, these junctions allow passage of small nonelectrolytes such as erythritol, mannitol,\textsuperscript{122} and sucrose,\textsuperscript{123} suggesting that they are large enough to permit appreciable osmotic water flow during bile fluid formation.

The initial event in mechanical bile duct obstruction is an increase in common duct pressure, which is transmitted back

Figure 5 Role of OATP in CB homeostasis in normal subjects with a serum CB concentration of 0.012 mg/dL.

Notes: (A) Conventional view, in which plasma CB is determined by a relatively small biliary or hepatic cell leak of CB (0.14 mg/day) into the plasma which is balanced solely by renal excretion. (B) The newly postulated situation, in which there is a much more rapid CB leak (62.3 mg/day) that is countered by a very efficient OATP-facilitated reuptake by the hepatocyte.

Abbreviations: CB, conjugated bilirubin; UB, unconjugated bilirubin; UGT, uridine diphosphate glycosyltransferase.
into the canaliculi of the liver. After bile duct ligation in dogs, the bile duct pressure increases from the normal value of 10 cm H₂O to 40 cm H₂O after 2 days and is then maintained at this value for up to 28 days. Since this 40 cm hydrostatic pressure is equivalent to an osmotic pressure of only about 2 mOsm, it should not alter the osmotic bile formation rate. The most probable pathway for the leak of bile back into the systemic circulation is via the intercellular tight junctions (Figure 7). This is directly supported by bile duct ligation studies showing histological changes in the hepatocyte tight junctions and leakage of horseradish peroxidase into the pericanalicular space. Since the bilirubin in bile is nearly 100% conjugated (see “Bilirubin transport from hepatocyte to bile”), initially this paracellular leak should increase only serum CB concentration. This is what was observed by Sieg et al in 20 patients with acute obstruction due to common duct stones, in whom there was, on average, a 15-fold increase in TB, a 560-fold increase in CB, and no statistically significant increase in UB (see Table 1).

In contrast to the findings in acute obstruction, there is also an increase in unconjugated plasma bilirubin in chronic obstruction, although most (usually >80% of the total) of the increase is in the conjugated form. This unconjugated increase presumably results, in part, from a loss of liver deconjugation function produced by the dramatic changes in liver histology, biochemistry, and cell death that occur after several days of obstruction.

Hyperbilirubinemia is said to result from “intrahepatic cholestasis” when, in the absence of extrahepatic obstruction, CB comprises a high fraction of the TB, alkaline phosphatase is elevated out of proportion to other measurements of liver function (eg, aminotransferases), and bilirubin accumulations...
Figure 7 Processes involved in bile formation and bilirubin secretion.

Notes: Bile salts are transported into the liver primarily by a Na⁺ bile symport transporter (NTCP/SLC10A1) plus a small contribution from OATs. The canalicular bile fluid secretion results from the osmotic pressure produced by the ATP-dependent active transport of the bile salts (BSEP/ABCB11 transporter), as well as CB (MRP transporters) and other metabolites, into the canaliculus. This osmotic water flow occurs through the cell membrane and the intracellular tight junctions (solid arrows). Increased canalicular pressure produced by bile duct obstruction produces leakage of bile into the sinusoid through the ruptured tight junctions (red dashed line). The leaked CB may be taken back up into the hepatocyte by the OATP transport proteins (red dashed line).

Abbreviations: CB, conjugated bilirubin; UB, unconjugated bilirubin; UGT, uridine diphosphate glycosyltransferase.

are noted in liver biopsies. Unlike extrahepatic mechanical bile duct obstruction, which has a clearly defined pathology and good experimental models, the diverse heterogeneous conditions grouped under intrahepatic cholestasis are rather poorly understood and characterized. Intrahepatic cholestasis has multiple etiologies, including liver infections (viral, bacterial, and fungal), sepsis, autoimmune diseases, sarcoidosis, amyloidosis, lymphoma, heart failure, drug reactions (eg, antibiotics, anti-inflammatories, and oral contraceptives). The elevation of CB may result from obstructed bile flow, altered bile ductular integrity, or reduced production of bile due to defective activity of the bile efflux transporters (eg, BSEP, MRPs [Figure 7]). The latter is thought to be the cause of cholestasis of pregnancy, a condition characterized by high serum bile acid concentrations and CB-predominant, mild hyperbilirubinemia (Table 1). There is suggestive evidence that high estrogen and progesterone metabolite concentrations that develop in late pregnancy inhibit the bile acid transporters.

Bilirubin enterohepatic circulation

The black dashed line in Figure 1 refers to the enterohepatic circulation of bilirubin that is normally small but which may become important in some clinical situations. In the gut, nonabsorbable CB can be irreversibly degraded by bacteria to relatively impermeable urobilinoids or deconjugated by β-glucuronidase to highly membrane-permeable, absorbable UB (Figure 1). At least 25% of orally administered ¹⁴C-labeled UB is absorbed in humans, while only a small percent of ¹⁴C-labeled CB is recycled. Thus, under physiological conditions, catabolism to urobilinoids predominates. However, in some circumstances, deconjugation can apparently lead to recirculation of a substantial portion of bilirubin, appreciably increasing the bilirubin load to the liver.

Enterohepatic circulation has been proposed as a contributing factor to the physiologic jaundice of newborns. Vítek et al found that fecal UB rose from a value of 169 nmol/g dry weight on day 1 after birth to a peak of 2,204 on day 5 and then, by 6 weeks, fell 15-fold as the colon was colonized by bacteria. In contrast, urobilinoids were not detectable until day 5 and then increased tenfold over the following 6 weeks. Thus, the bacterial flora of the newborn favors the deconjugation of CB to UB over urobilinoid production with a resultant increase in the enterohepatic circulation of UB. The origin of this β-glucuronidase activity present in infant feces could be bacterial, intestinal, or the mother’s milk, with the last thought to play a role in breast milk jaundice. A study involving feeding of agar to newborns provides direct support for the concept that the intralumi-
nal milieu plays a role in UB homeostasis. In untreated infants, the normal “physiologic” serum bilirubin increase was observed, peaking on day 4 at a value 83% higher than on day 1, while, in agar-treated infants, serum bilirubin fell continuously after birth to a value on day 6 that was 45% less than on day 1. Correspondingly, the total fecal bilirubin excretion in the agar-treated infants was about three times greater than that of the untreated over the first 5 days after birth. Presumably, by an unknown mechanism, agar inhibits deconjugation of CB with a resultant decrease in absorption of UB.

Enterohepatic circulation has also been invoked as a possible causative factor for “fasting hyperbilirubinemia”. Serum UB increases 80% from a mean of 0.5 to 0.9 mg/dL in normal subjects after a 48-hour fast (300 kcal provided). The increase is more dramatic in Gilbert’s syndrome, increasing from 1.5 to 3.5 mg/dL (130%), and fasting is used as a diagnostic test for this syndrome. Despite considerable study, this response to fasting remains a poorly understood phenomenon. Based on CO measurements, it was initially proposed that fasting increases heme catabolism, but this observation was not confirmed in a subsequent study.

A second postulate was that caloric deprivation decreases hepatic glucuronidation activity. However, fasting-induced elevation of serum UB in Gilbert’s subjects was not prevented by an intravenous infusion of either glucose or lipid with the same caloric load (2,400 kcal) as in the standard oral diet. The most recent hypothesis is that fasting slows small intestinal transit, allowing more time for the conversion of CB to UB in the small intestine. The correspondingly larger increase in Gilbert’s subjects could reflect partial saturation of the defective hepatic UB deconjugation system due to the recirculated load. An alternative explanation is that the fraction of monoconjugated bilirubin in the bile of Gilbert’s subjects (94%) is higher than that of normal subjects (37%), thus the CB of Gilbert’s is more readily deconjugated in the gut to UB. However, quantitative considerations cast doubt on the concept that increased enterohepatic circulation could account for the entire 80% increase in serum bilirubin observed in fasting normal subjects. Assuming the steady state is reached after 2 days of fasting and hepatic bilirubin secretion is first order, the 80% increase requires that at least 45% of the secreted bilirubin be recirculated. Thus, the hypothesis that fasting hyperbilirubinemia is attributable to an increased enterohepatic circulation is attributable to an increased enterohepatic circulation requires an enormous alteration in the gut metabolism of CB, with a shift from the normal, near-complete bacterial conversion to urobinoids to a situation where there is at least 45% deconjugation (and absorption) of CB in the gut. This seems unlikely, since only 25% of ingested 14C-labeled UB was absorbed by healthy subjects.

Recirculation has also been postulated to explain other observations, such as a nearly twofold increase in total biliary secretion of bilirubin produced by ileal resection in the rat, requiring an unlikely scenario in which about 50% of secreted CB was recirculated. Similarly, a statistically significant 30% increase in serum UB observed with oral chenodeoxycholic acid in humans was attributed to a solubilizing effect that allowed increased enterohepatic circulation of UB. If increased absorption of bilirubin can truly reach 30%–50% of the secreted bilirubin, this process would have important implications for the interpretation of serum bilirubin measurements.

Summary and clinical implications

The regulation of serum bilirubin concentration is far more complex than that of other serum analytes used to assess organ function. For example, serum creatinine concentration is determined by glomerular filtration rate and serum amino transferases by the rate of hepatocellular release of the enzymes. In contrast, bilirubin homeostasis is a complex process involving multiple organs, enzyme reactions, and membrane transport systems. Total serum bilirubin represents the sum of the concentrations of UB and CB, each of which has its own homeostatic regulation (Figure 1). The steady-state concentration of each form of bilirubin is established when its plasma concentration reaches a level that permits plasma removal at a rate equal to its delivery to the plasma. A variety of factors limit both the sensitivity and the specificity of bilirubin measurements to detect the abnormalities illustrated in Figure 1 and listed in Table 1.

Serum bilirubin is commonly assessed as part of routine physical examinations as well in the evaluation of virtually all sick patients. The primary purpose of these measurements is to determine if: 1) the total serum bilirubin is elevated, which (in the absence of an increased bilirubin load) is indicative of liver malfunction; 2) the bilirubin elevation results from an isolated increase of UB, which is indicative of an increased bilirubin load (hemolysis or increased enterohepatic circulation), or from a genetically acquired conjugating defect; 3) the bilirubin elevation reflects a predominance (>70%) of CB, which suggests cholestatic (as opposed to hepatocellular) liver disease; or 4) the UB and CB are roughly equal, a finding suggestive of hepatocellular disease.

What constitutes a normal diazo total serum bilirubin concentration varies by laboratory, with normal values commonly...
considered to range from a low of 0.1 mg/dL to a high of 1–1.2 mg/dL (Table 1). In the very large Third National Health and Nutrition Examination Survey (NHANES III) study of 16,865 randomly selected US adults, the 2.5 and 97.5 percentile values for TB using the standard diazo assay were 0.2 mg/dL and 1.4 mg/dL, respectively. While the modal value was 0.4 mg/dL, there was a marked skewing toward higher values, with the mean value being 0.62 mg/dL. The authors attributed this relatively high normal range to their subjects’ fasting state, a confounding factor known to increase serum UB in both normal subjects and subjects with Gilbert’s syndrome (see “Bilirubin enterohepatic circulation”). While the TB was not fractionated in this study, UB commonly represents the vast majority of the bilirubin of healthy subjects. The tendency of the data to skew toward higher values is commonly attributed to subjects with reduced activity of UGT1A1, ie, subjects with Gilbert’s syndrome. The frequency of Gilbert’s in the healthy population has been variously cited to range from 5% to 15% of the population. However, the possible role of an increased bilirubin load due to decreases in RBC survival, increased cytochrome turnover, or increased UB absorption from the gut has not been excluded as a contributory factor toward the unusually high UB observed in some apparently healthy subjects.

The high frequency of Gilbert’s in the general population appreciably reduces the sensitivity of TB as an indicator of liver malfunction. For example, if a patient with a baseline modal TB value of 0.4 mg/dL developed a cholestatic problem, CB must increase from the true, chromatographic (HPLC) normal value of about 0.012 mg/dL to 1.0 mg/dL simply to reach the TB upper limit of normal of 1.4 mg/dL, roughly an 80-fold increase in CB. While routine HPLC measurement of CB could be a more sensitive indicator of liver dysfunction than the presently employed diazo technique, minor increases in CB might be so nonspecific as to confuse rather than enhance clinical management of patients.

The wide normal variability of UB concentration also limits the value of this measurement as a means of identifying the presence of low-to-moderately severe hemolysis. Roughly 75% of the bilirubin load (about 0.3 mg/dL of the modal 0.4 mg/dL in normal serum) is derived from breakdown of circulating erythrocytes. Thus, in a non-anemic subject, the survival of RBCs (normally 120 days) would have to be reduced by about 3.7-fold, to 32 days, to elevate the UB to 1.4 mg/dL. When employed to identify hemolysis in a subject with anemia, RBC survival has to be even more deranged to elevate UB above the upper limit of normal, eg, in a subject with a hemoglobin of 7 g/dL (50% reduction from the normal 14 g/dL), RBC survival would have to be reduced by roughly 7.4-fold (to 16 days) in order to produce a detectable increase in UB.

Hyperbilirubinemia results from disorders of one or more of the metabolic steps outlined in Figure 1. Measurements of CB and UB in hyperbilirubinemia provide direction for additional diagnostic tests but almost never provide sufficient information with which to identify the specific disorder(s) causing the problem. A marked predominance (>80%) of UB in hyperbilirubinemia is indicative of a major increase in the bilirubin load (eg, hemolysis), a conjugating defect (eg, Gilbert’s or Crigler–Najjar syndromes), or, possibly, increased enterohepatic circulation of UB. While bilirubin production could be estimated via measurements of CO excretion, such testing is not clinically available. Thus, an increased bilirubin load is commonly imputed from results of indirect indicators of hemolysis (blood smear, haptoglobin, reticulocyte count, and lactate dehydrogenase) in the anemic patient. UB derived from liver enzymes or absorption following deconjugation of CB in the gut remain potential sources of UB that cannot be quantitated using available tests. With an increased bilirubin load (eg, hemolysis), both UB and CB (measured via HPLC) increase in direct proportion to the total load. However, as discussed in the section “CB transport from hepatocyte to blood”, this relatively small CB increase from normal (eg, up to eightfold) is not detectable with the diazo CB assay because of background contaminants. If patients also have an increased CB concentration due to underlying liver disease, then this superimposed increased bilirubin load would produce appreciable increases in CB that are measurable with the diazo reaction. In the absence of hemolysis, UB-predominant hyperbilirubinemia is assumed to reflect decreased CB conjugation (ie UGT1A1 deficiency): Gilbert’s when the UB is <3 mg/dL and Crigler–Najjar when the UB is >3 mg/dL.

A marked predominance (>70%) of CB in hyperbilirubinemia is strongly suggestive of cholestasis secondary to extrahepatic or intrahepatic disease (Table 1 [last six entries]). Extrahepatic obstruction to bile flow is usually caused by gallstones, malignancy, or benign strictures. The resultant increased pressure in the biliary system produces reflux of CB into the plasma. Intrahepatic cholestasis can be caused by obstruction to bile flow in the liver (primary biliary cirrhosis or hepatic mass lesions), lack of integrity of the biliary canaliculi, or decreased bulk secretion of bile secondary to drugs or other conditions (possibly sepsis) that diminish the bile acid secretion that drives bile flow. In addition, rare congenital defects that reduce transport of CB into the canaliculus (Dubin–Johnson) or reduce uptake
of CB from the blood (Rotor) can produce CB-predominant hyperbilirubinemia. Measurements of bilirubin or other liver function tests seldom identify the etiology of predominant conjugated hyperbilirubinemia, and evaluation with endoscopic, radiographic, serology, or biopsy procedures are required to pinpoint the specific problem.

When there is not a predominance of either UB or CB, hyperbilirubinemia is usually the result of what is termed a “hepatocellular” problem, such as various forms of hepatitis or cirrhosis (Table 1). The seemingly simple observation that UB and CB maintain roughly comparable serum concentrations in hepatocellular disease actually requires the interplay of several unusual phenomena that have received little or no attention in the literature. First, CB must rise by about 30-fold simply to reach the normal serum concentration of UB (0.4 mg/dL). What mechanism could be so disordered in relatively mild hepatocellular dysfunction that normal CB clearance is diminished by 30-fold? Such an alteration from normal function is virtually unknown with any other organ system. Second, some linkage between CB and UB clearance would be necessary to maintain these compounds at relatively similar concentrations over wide ranges of bilirubin concentrations in a variety of hepatocellular disease.

As discussed in the section “CB transport from hepatocyte to blood”, the implications of the recent observation of a large OATP-mediated CB recirculation and clearance of about 0.36 L/minute profoundly alters the interpretation of the increased serum CB observed in these diseases. If this OATP clearance remains at its normal value, then just a moderate increase in serum CB (eg, 0.36 mg/dL [Figure 6]) implies that there would have to be an enormous CB leak of 1,870 mg (seven times the total daily UB production). Thus, it is seemingly impossible for CB to rise to the concentrations observed in hepatocellular disease if OATP function remains largely intact. While totally speculative, it seems necessary to postulate that defects in OATP function occur early in the course of hepatocellular disease. Such defects would permit relatively enormous increases in serum CB due simply to the failure to recycle the normal leak of bilirubin from hepatocyte to plasma (which would be aggravated by additional leakage in liver disease). The primary role of bilirubin recycling in the maintenance of serum CB concentration has not been previously recognized and obviously requires further study.

The second “mystery” of serum bilirubin concentrations in hepatocellular disease is the maintenance of roughly similar serum concentrations of CB and UB, despite the fact that these compounds are controlled by very different homeostatic mechanisms. It should be stressed that when CB and UB have similar serum concentrations, there has been a 30-fold increase over normal for CB relative to the increase for UB. Thus, the similar serum levels of the two forms of bilirubin in hepatocellular diseases requires that CB:UB clearances be reduced in a constant ratio of roughly 30:1. It seems highly unlikely that tissue damage would be consistently around 30-fold more injurious to the normal CB excretory mechanism than it is to UB excretion; rather, it seems likely that the clearance of the two types of bilirubin is linked by some factor wherein the rise of one bilirubin species feeds back on the clearance of the other. There is no evidence that an elevated UB concentration inhibits the excretion of CB, since CB remains normal in hemolytic states or Gilbert’s syndrome. In contrast, an elevated CB seems to inhibit UB conjugation, since, in the conjugated hyperbilirubinemas in Table 1 (last six entries), UB rises, albeit not in proportion to CB. One possible explanation for this CB inhibition of conjugation is competitive inhibition of the UGT1A1 enzyme by increased hepatocyte CB. As discussed in the section “Bilirubin glucuronidation and UB excretion”, both the mono- and diglucuronides of bilirubin are competitive inhibitors of UGT1A1. The hepatocyte influx and efflux transporters should maintain a proportional cell/plasma concentration ratio (see “CB transport from hepatocyte to blood”) and, for example, in Dubin–Johnson syndrome, the 200-fold increase in serum CB would correspond to a 200-fold increase in hepatocyte CB, which could competitively decrease the glucuronidation rate and produce the observed fourfold increase in serum UB.

There are two other factors that could contribute to the concomitant elevation of serum UB and CB in hepatocellular diseases. The first is the superimposition of an increased bilirubin load. For example, about one-third of the tenfold UB increase observed in alcoholic cirrhosis (Table 1) could be explained by the two- to threefold increase in bilirubin load secondary to diminished RBC survival in cirrhosis. The second is a reduction in the mass of functioning liver as a result of scarring and cell death. It would be valuable to be able to determine what component of the increase in TB is due simply to a loss of general liver function, since it would provide a quantitative measure of the extent of liver damage (for example, a tenfold increase in TB would indicate a 90% loss of liver function). One approach to quantitating liver function is to measure the hepatic clearance of drugs such as indocyanine green, sulfobromophthalein, antipyrine, or aminopyrine. The clearance of all four of these com-
pounds is reduced by an average factor of three or more in alcoholic cirrhosis,\textsuperscript{152–154} which, if they are an indication of liver cell loss, should produce a threefold increase of TB. To the extent that bilirubin clearance is influenced by the same general lack of functional liver that reduces the clearance of these test compounds, there should be a relatively linear relationship between the fractional increase in TB and the inverse of the fractional decrease in the hepatic drug clearance. Figure 8 shows this plot for the clearance of these four different compounds in patients with chronic alcoholic cirrhosis. Although there is considerable scatter, this relationship is roughly confirmed, with about 50% of the increase in TB explained by a general decrease in liver function, with the other 50% possibly produced by some other liver malfunction that might also account for the 30-fold increase in CB relative to UB.

The precise serum bilirubin concentration is one of the measurements commonly employed for the calculation of “scores” that predict the prognosis and direct therapeutic interventions in patients with liver disease (eg, MELD, Child–Pugh, Maddrey, and FibroTest). The use of and weighting of the TB measurement in these calculations is based on empirical observation that an increase in total serum bilirubin is one of the strongest correlates with poor patient outcome in hepatocellular disease.\textsuperscript{155} While it seems intuitively obvious that the serum bilirubin level would serve as a marker of the degree of liver dysfunction, several factors not directly related to liver function may have a sizable effect on the serum bilirubin concentration. For example, both UB and CB will vary directly with the bilirubin load. Hence, RBC life span that is frequently, but variably, reduced in severe liver disease could induce several-fold differences in serum bilirubin concentrations of patients with equal abilities to clear bilirubin. Similarly, variations in enterohepatic circulation of bilirubin could influence serum bilirubin concentrations. Lastly, the presence of δ-bilirubin influences the serum concentration of CB by a mechanism independent of liver function. Thus, it seems possible that bilirubin measurements corrected for bilirubin load and δ-bilirubin would serve as a more precise measure of liver function and, possibly, a more accurate indicator of prognosis.

This positive correlation between the degree of hyperbilirubinemia and prognosis of liver disease patients is expected. More surprising are the repeated observations of an inverse correlation between serum bilirubin concentrations and a variety of potentially lethal conditions in subjects who do not have liver disease. Higher bilirubin levels have been associated with a decreased incidence of coronary disease, rectal cancer, and diabetes.\textsuperscript{150,156} In a large life insurance study of apparently healthy males less than 60 years of age, mortality over a 10- to 14-year period was about 2.6 times higher for subjects with a serum bilirubin of 0.3 mg/dL versus a bilirubin of 1.1–1.3 mg/dL.\textsuperscript{157}

It will be important to determine if lower serum bilirubin concentrations are a cause or an effect of ill health. As discussed in the current review, the serum bilirubin of patients without liver disease is virtually all UB, and the serum level of this compound is a function of the bilirubin load, albumin binding, and the activity of UGT1A1. It seems unlikely that low bilirubin concentrations are a result of decreased UB production, since this would require a substantial increase in RBC life span. As discussed in the section “Bilirubin glucuronidation and UB excretion”, serum UB is inversely proportional to the albumin dissociation constant, as exemplified by patients on hemodialysis who have serum UB concentrations that are 25% of normal because of decreased albumin binding of UB. It seems possible that some yet-to-be-identified factor associated with ill health could decrease the binding of UB to albumin. It is also possible that such an unknown factor might enhance UGT1A1 activity. In these hypothetical cases, low UB would simply be a marker of the propensity to develop disease. More interesting would be the situation in which high serum UB is protective against various diseases, possibly via its antioxidant effect. Such a protective effect would provide a biological rationale for the complicated handling of UB that ensures appreciable (µM) serum concentrations of this compound. Research on bilirubin, a

![Figure 8](image-url)
relatively dormant area of investigation at present, would be greatly invigorated if UB could be shown to protect against important diseases and reduce mortality.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Papavramidou N, Fee E, Christopoulou-Aletra H. Jaundice in the Hippocratic Corpus. J Gastrointest Surg. 2007;11(12):1728–1731.
2. van den Bergh AAH, Muller P. Über eine direkte und eine indirekte Diazoreaktion auf Bilirubin [About a direct and an indirect diazo reaction to bilirubin]. Biochem Z. 1916;77:90–103. German.
3. Billing BH, Cole PG, Lathe GH. The excretion of bilirubin as a diglucuronide giving the direct van den Bergh reaction. Biochem J. 1957; 65(4):774–784.
4. Talafant E. Properties and composition of the bile pigment giving a direct diazo reaction. Nature. 1956;178(4528):312.
5. Blanckaert N, Fevery J. Physiology and pathophysiology of bilirubin metabolism. In: Zakim D, Boyer TD, editors. Hepatology: A Textbook of Liver Disease. Vol 1. 2nd ed. Philadelphia, PA: WB Saunders; 1990:254–302.
6. Roy-Chowdhury J, Roy-Chowdhury N. Bilirubin metabolism and its disorders. In: Boyer TD, Mans P, Sanyal AJ, Zakim D, editors. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012:1079–1109.
7. Mitylb GL, Chandrashekar Y, Furne JK, Levitt MD. Use of breath carbon monoxide to measure the influence of prosthetic heart valves on erythrocyte survival. Am J Cardiol. 2006;97(9):1374–1376.
8. Mitylb GL, Singh JA, Furne JK, Ruddy J, Levitt MD. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol. 2006;81(6):432–438.
9. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007;8(10):766–775.
10. Mancuso C, Navarra P, Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010;113(3):563–575.
11. Rochette L, Cottin Y, Zeller M, Vergely C. Carbon monoxide: mechanisms of action and potential clinical implications. Pharmacol Ther. 2013;137(2):133–152.
12. Vitke L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. J Lipid Res. 2013;137(2):133–152.
13. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043–1046.
14. Mancuso C, Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr Drug Metab. 2009;10(6):579–594.
15. Gibbs PE, Tudor C, Maines MD. Biliverdin reductase: more than a namesake – the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front Pharmacol. 2012;3:31.
16. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99(25):16093–16098.
17. Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular anti-oxidant protection by biliverdin reductase. J Biol Chem. 2009;284(43):29251–29259.
18. McDonagh AF. The biliverdin-bilirubin antioxidant cycle of cellular protection: missing a wheel? Free Radic Biol Med. 2010;49(5):814–820.
19. Barone E, Trombino S, Cassano R, et al. Characterization of the S-dentrosylating activity of bilirubin. J Cell Mol Med. 2009;13(8B):2365–2375.
20. Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G. Albumin-bound bilirubin interacts with nitric oxide by a redox mechanism. Antioxid Redox Signal. 2006;8(3–4):487–494.
21. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys. 1998;352(2):165–174.
22. Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J. 2010;51(2):86–91.
23. Tell G, Gustinich C. Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. Curr Pharm Des. 2009;15(25):2908–2914.
24. Turfan M, Duran M, Poyraz F, et al. Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease. Coron Artery Dis. 2013;24(1):29–32.
25. Vitek L, Jirs M, Brodanová M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160(2):449–456.
26. Bennett R, Davies JE, Hurthouse MB, Sheldrick GM. The structure of bilirubin. Proc R Soc Lond B Biol Sci. 1978;202(1147):249–268.
27. Brodersen R, Stern L. Binding of bilirubin to albumin. Crit Rev Clin Lab Sci. 1980;11(4):305–399.
28. Hahn JS, Ostrow JD, Mukerjee P, Celci L. Ionization and self-association of unconjugated bilirubin, determined by rapid solvent partition from chloroform, with further studies of bilirubin solubility. J Lipid Res. 1992;33(8):1123–1137.
29. Wennberg RP. The blood-brain barrier and bilirubin encephalopathy. Cell Mol Neurobiol. 2000;20(1):97–109.
30. Zucker SD, Goessling W, Hoppin AG. Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes. J Biol Chem. 1999;274(16):10852–10862.
31. Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003;3:3.
32. Simons PC, Jagt DL. Bilirubin binding to human liver ligandin (glutathione S-transferase). J Biol Chem. 1980;255(10):4740–4744.
33. Scheidt PC, Mellits ED, Hardy JB, Drage JS, Boggs TR. Toxicity modulator of neurotrophin redox signaling. Neuromolecular Med. 2006;8(4):513–529.
34. Mancuso C, Capone C, Ranieri SC, et al. Bilirubin as an endogenous S-denitrosylating activity of bilirubin. Proc Natl Acad Sci U S A. 2002;99(25):16093–16098.
35. Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem. 2009;284(43):29251–29259.
36. McDonagh AF. The biliverdin-bilirubin antioxidant cycle of cellular protection: missing a wheel? Free Radic Biol Med. 2010;49(5):814–820.
43. Doumas BT, Wu TW. The measurement of bilirubin fractions in serum. Crit Rev Clin Lab Sci. 1991;28(5–6):415–445.
44. Dutt MK, Murphy GM, Thompson RP. Unconjugated bilirubin in human bile: the nucleating factor in cholesterol cholelithiasis? J Clin Pathol. 2003;56(8):596–598.
45. Fulop M, Sandson J, Brazeau P. Dialyzability, protein binding, and renal excretion of plasma conjugated bilirubin. J Clin Invest. 1965; 44:666–680.
46. Cameron JL, Stafford ES, Schnaufer L, Iber FL. Bilirubin excretion in the dog. J Surg Res. 1963;3:39–42.
47. Fulop M, Brazeau P. Impaired renal function exaggerates hyperbilirubinemia in bile duct-ligated dogs. Am J Dig Dis. 1970;15(12):1067–1072.
48. Cameron JL, Filer RM, Iber FL, Abei T, Randolph JG. Metabolism and excretion of C14-labeled bilirubin in children with biliary atresia. N Engl J Med. 1966;254(5):231–236.
49. Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med. 1983;309(3):147–150.
50. Beeken WL, Volwiler W, Goldsworthy PD, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest. 1962;41:1312–1333.
51. Ferrery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28(5):592–605.
52. Hardman JG, Limbird LE, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001.
53. Guillemette C, Lévesque E, Harvey M, Bellemare J, Menard V. UGT genomic diversity: beyond gene duplication. Drug Metab Rev. 2010;42(1):24–44.
54. Bock KW. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem Pharmacol. 2010;80(6):771–777.
55. Burchell B, Blancaert N. Bilirubin mono- and di-glucuronide formation by purified rat liver microsomal bilirubin UDP-glucuronosyltransferase. Biochem J. 1984;223(2):461–465.
56. Skierka JM, Kotzer KE, Lagerstedt SA, O’Kane DJ, Baudhuin LM. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. J Pediatr. 2013;162(6):1146–1152, 1152c–e2.
57. Ferrery J, Blancaert N, Heirwegh KP, Préaux AM, Berthelot P. Bilirubin mono- and diglucuronide formation in vitro: position of bilirubin in rats with unconjugated hyperbilirubinemia. Crit Rev Clin Lab Sci. 1991;28(5):1266–1271.
58. McDonagh AF. Controversies in bilirubin biochemistry and their clinical relevance. Crit Rev Clin Lab Sci. 2003;37(1):20695–20699.
59. Wang P, Kim RB, Chowdhry JR, Wolkoff AW. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem. 2003;278(23):20695–20699.
60. White JK, Gerdin AK, Karp NA, et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responding to unconjugated bilirubin and an increased proportion of bilirubin unconjugated hyperbilirubinemia. Liver Int. 2010;34(1):141–147.
61. Iga T, Eaton DL, Klaassen CD. Uptake of unconjugated bilirubin by isolated rat hepatocytes. Am J Physiol. 1979;236(1):C9–C14.
62. Black M, Billing BH. Hepatic bilirubin udp-glucuronosyl transferase activity in liver disease and Gilbert’s syndrome. N Engl J Med. 1969;280(23):1266–1271.
63. Chowdhry JR, Chowdhry NR, Wu G, Shouval R, Arias IM. Bilirubin mono- and diglucuronide formation by human liver in vitro: assay by high-pressure liquid chromatography. Hepatology. 1981;11(6):622–627.
64. Zhou J, Tracy TS, Rennel RP. Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos. 2010;38(11):1907–1911.
65. Crone C. The permeability of capillaries in various organs as determined by use of the ‘indicator diffusion’ method. Acta Physiol Scand. 1963;58:292–305.
66. Zelenka J, Lenicek M, Muchova L, et al. Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):37–42.
67. Muchova L, Vanoka K, Zelenka J, et al. Bilirubin acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress. J Cell Mol Med. 2011;15(5):1156–1165.
68. Wolkoff AW, Ketley JN, Wagggoner JG, Berk PD, Jakoby WB. Hepatic accumulation and intracellular binding of conjugated bilirubin. J Clin Invest. 1978;61(1):142–149.
69. Wolkoff AW, Goresky CA, Sellin J, Gaymanait Z, Arias JM. Role of ligandin in transfer of bilirubin from plasma into liver. Am J Physiol. 1979;236(6):E638–E648.
70. Oie S, Levy G. Effect of salicylic acid on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharmacol. 1979;68(1):1–6.
71. Oie S, Levy G. Effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharmacol. 1979;68(1):6–9.
72. Fukui M, Tanaka M, Yamazaki M, et al. Low serum bilirubin concentration in haemodialysis patients with Type 2 diabetes. Diabet Med. 2011;28(1):96–99.
73. Tsutsui Y, Maruyama T, Takadate A, Shimada H, Otagiri M. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron. 2000;85(1):60–64.
74. Oie S, Lowenthal DT, Levy G. Protein binding of bilirubin in plasma of anephric patients. J Dial. 1980;4(2–3):91–100.
75. Tsutsui Y, Maruyama T, Takadate A, Goto M, Matsunaga H, Otagiri M. Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res. 1999;16(6):916–923.
76. Weisger RA. Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver. Proc Natl Acad Sci U S A. 1985;82(5):1563–1567.
77. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics. 2002;12(6):635–645.
78. Kuelh GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005; 33(7):1027–1035.
79. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001;98(22):12671–12676.
80. Crawford JM, Ransil BJ, Narciso JP, Gollan JL. Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis. J Biol Chem. 1992;267(24):16943–16950.
81. Schmid R, Hammaker L. Metabolism and disposition of C14-bilirubin in congenital nonhemolytic jaundice. J Clin Invest. 1963;42:1720–1734.
82. Kotal P, Van der Vree CN, Sinaasappel M, et al. Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia. Pediatr Res. 1997;42(2):195–200.
83. Gordon ER, Shaffer EA, Saks-Kortas A. Bilirubin secretion and conjugation in the Crigler-Najjar syndrome type II. Gastroenterology. 1976;70(5 Pt 1):761–765.
84. Sinaasappel M, Jansen PL. The differential diagnosis of Crigler-Najjar disease, types 1 and 2, by bile pigment analysis. Gastroenterology. 1991;100(3):783–789.
85. Hafkamp AM, Havinga R, Ostrow JD, et al. Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats. Pediatr Res. 2006;59(4 Pt 1):506–512.
86. Van Der Vree CN, Schoemaker B, Bakker C, Van der Meer R, Jansen PL, Elferink RP. Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia. Hepatology. 1996;24(3):620–626.
87. Van der Veere CN, Jansen PL, Sinaasappel M, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology. 1997;112(2):455–462.

88. Levitt DG. Quantitation of small intestinal permeability during normal human drug absorption. BMC Pharmacol Toxicol. 2013;14:34.

89. Iihara H, Hashizume N, Shimizu N, Aoki T. Threshold concentration of unbound bilirubin to induce neurological deficits in a patient with type 1 Crigler-Najjar syndrome. Ann Clin Biochem. 1999;36(3):347–352.

90. Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM, Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM. 1999;158 Suppl 2:S89–S94.

91. Arias IM. Studies of chronic familial non-hemolytic jaundice with conjugated bilirubin in the serum with and without an unidentified pigment in the liver cells. Am J Med. 1961;31(4):510–518.
129. Georgiev P, Johcum W, Heinrich S, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg. 2008;95(5):646–656.

130. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology. 1999;117(3):669–677.

131. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–276.

132. Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013;17(2):301–317.

133. Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17(2):191–209.

134. Brites D, Rodrigues CM, van-Zeller H, Brito A, Silva R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur J Obstet Gynecol Reprod Biol. 1998;80(1):31–38.

135. Castaño G, Lucangioli S, Sookoian S, et al. Bile acid profiles by capillary electrophoresis in intrahepatic cholestasis of pregnancy. Clin Sci (Lond). 2006;110(4):459–465.

136. Abu-Hayyeh S, Papacleovoulou G, Lövgren-Sandblom A, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology. 2013;57(2):716–726.

137. Lester R, Schmid R. Intestinal absorption of bile pigments. II. Bilirubin absorption in man. N Engl J Med. 1963;269:178–182.

138. Vítek L, Kotal P, Vítek L, Fevery J. Fasting-related hyperbilirubinemia in neonatal jaundice. J Pediatr Gastroenterol Nutr. 2000;30(3):294–298.

139. Gollan JL, Bateman C, Billing BH. Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome. Gut. 1976;17(5):335–340.

140. Gärnter U, Goeser T, Wolkoff AW. Effect of fasting on the uptake of bilirubin and sulfobromophthalein by the isolated perfused rat liver. Gastroenterology. 1997;113(5):1707–1713.

141. Kotal P, Vítek L, Favery J. Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. Gastroenterology. 1996;111(1):217–223.

142. Favery J. Fasting hyperbilirubinemia: unraveling the mechanism involved. Gastroenterology. 1997;113(5):1798–1800.

143. Brink MA, Mendez-Sanchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology. 1996;110(6):1945–1957.

144. Thistle JL, Hofmann AF. Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. N Engl J Med. 1973;289(13):655–659.

145. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40(4):827–835.

146. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic factors of intrahepatic cholestasis of pregnancy. Hepatology. 2006;44(1):217–231.

147. Fevery J. Fasting hyperbilirubinemia: unraveling the mechanism involved. Gastroenterology. 1997;113(5):1798–1800.

148. Brink MA, Mendez-Sanchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology. 1996;110(6):1945–1957.

149. Thistle JL, Hofmann AF. Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. N Engl J Med. 1973;289(13):655–659.

150. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40(4):827–835.

151. Raedsch R, Stiehl A, Gundert-Remy U, et al. Hepatic secretion of bilirubin and biliary lipids in patients with alcoholic cirrhosis of the liver. Digestion. 1983;26(2):80–88.

152. Cherrick GR, Stein SW, Levy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960;39:592–600.

153. Branch RA, James JA, Read AE. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease. Clin Pharmacol Ther. 1976;20(1):81–89.

154. Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975;83(5):632–638.

155. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.

156. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.

157. Fulls M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J Insur Med. 2009;41(1):49–53.